Pacific Edge at risk of losing ‘significant’ revenue stream

Pacific Edge at risk of losing ‘significant’ revenue stream
The test has been used more than 10,000 times since it was first approved in 2020. (Image: Pacific Edge)
Dan Brunskill
Pacific Edge could have its cancer tests dropped by a major US health insurance company which is considering a new way to choose which tests are covered.  Medicare provider Novitas currently reimburses the use of Cxbladder but would not under a new process it has proposed. Currently, the health insurer reviews clinical evidence for each individual product but has proposed relying on third-party lists instead. Pacific Edge said if the proposal was adopted, Cxbladder would no longer receive reimbursement from Novitas, which makes up &ld...

More Markets

NZ sharemarket claws back to end the week up 0.5%
Markets Market close

NZ sharemarket claws back to end the week up 0.5%

Index rumours drive prices on two shares. 

Graham Skellern 13 Dec 2024
Staff leave Meridian after retail 'reset'
Markets

Staff leave Meridian after retail 'reset'

Expect a very different approach from Meridian in 2025, executive says.

John Anthony 13 Dec 2024
NZX, NZSA want level playing field in climate reporting
Markets

NZX, NZSA want level playing field in climate reporting

Climate reporting liabilities for company directors could soon be eased.

Greg Hurrell 13 Dec 2024
Cannasouth delisting keeps Petterson in charge
Markets

Cannasouth delisting keeps Petterson in charge

Cannasouth major shareholders pushed to end voluntary administration they had called in.

Garth Bray 13 Dec 2024